AveXis (NASDAQ:AVXS) received a $110.00 price target from investment analysts at Canaccord Genuity in a research report issued to clients and investors on Thursday. The firm currently has a “hold” rating on the stock. Canaccord Genuity’s target price suggests a potential upside of 11.41% from the stock’s current price.

Several other research firms also recently weighed in on AVXS. BidaskClub downgraded AveXis from a “hold” rating to a “sell” rating in a research report on Thursday. Bank of America cut their target price on AveXis from $115.00 to $112.00 and set a “buy” rating on the stock in a research report on Friday, November 10th. BMO Capital Markets reissued an “outperform” rating and set a $130.00 target price (up previously from $123.00) on shares of AveXis in a research report on Thursday, October 12th. Wells Fargo & Company reissued an “outperform” rating and set a $134.00 target price (up previously from $89.00) on shares of AveXis in a research report on Tuesday, September 5th. Finally, Evercore ISI started coverage on AveXis in a research report on Wednesday, August 16th. They set an “outperform” rating and a $120.00 target price on the stock. Four research analysts have rated the stock with a sell rating, three have given a hold rating and thirteen have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $110.67.

AveXis (NASDAQ AVXS) traded up $0.39 during midday trading on Thursday, hitting $98.73. The stock had a trading volume of 291,253 shares, compared to its average volume of 426,203. AveXis has a 52-week low of $44.68 and a 52-week high of $108.27.

AveXis (NASDAQ:AVXS) last released its earnings results on Thursday, November 9th. The company reported ($1.52) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.48) by ($0.04). During the same quarter in the previous year, the company earned ($0.87) earnings per share. analysts forecast that AveXis will post -6.23 earnings per share for the current year.

In other news, VP Andrew F. Knudten sold 2,000 shares of the business’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $94.48, for a total value of $188,960.00. Following the completion of the transaction, the vice president now directly owns 7,000 shares of the company’s stock, valued at approximately $661,360. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Sukumar Nagendran sold 1,780 shares of the business’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $97.25, for a total value of $173,105.00. Following the completion of the transaction, the vice president now directly owns 1,780 shares of the company’s stock, valued at $173,105. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 52,340 shares of company stock valued at $5,172,298. 18.60% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in AVXS. Strs Ohio bought a new position in shares of AveXis in the 3rd quarter worth $116,000. Ameritas Investment Partners Inc. raised its position in shares of AveXis by 331.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,112 shares of the company’s stock worth $174,000 after acquiring an additional 1,622 shares in the last quarter. Cubist Systematic Strategies LLC raised its position in shares of AveXis by 688.6% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock worth $175,000 after acquiring an additional 1,577 shares in the last quarter. Teacher Retirement System of Texas bought a new position in shares of AveXis in the 3rd quarter worth $200,000. Finally, Deschutes Portfolio Strategy LLC bought a new position in shares of AveXis in the 3rd quarter worth $203,000. 92.88% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This story was originally published by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/12/14/avexis-avxs-given-a-110-00-price-target-by-canaccord-genuity-analysts.html.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.